Ultrasound
Cardio-oncology
Managing cardiotoxicity risks at every step
Because cancer patients have on average a 2-6 times higher cardiovascular disease mortality risk than the general population [1], prompt, reliable identification of at-risk patients is crucial. And once treatment is underway, close monitoring could help cardiologists detect potential biomarkers that may indicate the early stages of cardiotoxicity. The European Society of Cardiology (ESC) Guidelines for Cardio-oncology [2] reflect the priorities for the prevention and monitoring of cardiotoxicity risks.
Demonstrated results cardio-oncology
Solutions in line with ESC Guidelines on cardio-oncology
We are ready to support you and your patients every step of the way along their cancer treatment journey. Our MR and AI-based ultrasound solutions support a comprehensive baseline assessment and reduce variability between users. Powerful workflow solutions provide multidisciplinary cardio-oncology teams with a patient-centric overview.
Assess and manage cardiotoxicity with confidence
- Access patient data, including ECG, blood pressure, biomarker data and high-quality ultrasound images, in a longitudinal patient-centric view.
- Define robust baseline risk predictors for cardiotoxicity by performing ultrasound risk stratification assessments using a highly standardized, easy-to-follow approach.
- Capture superb MR images and robust quantification reports for accurate and consistent measurements that inform and guide the patient journey.
Advanced tools provide insights
- AutoStrain offers fast, consistent LVEF and LVGLS measurement on the same image with one button push.
- Dynamic HeartModel** measures 3D ejection fraction (3DEF) in seconds, harnessing AI for enhanced cardiac function assessments. [6]
- iRotate iRotate keeps the transducer in a fixed position, facilitating reproducible images and helping bridge the gap between 2D and 3D thinking.
- With the combination of Fast-SENC MR sequence and MyoStrain,* you can generate a quantitative report that can detect early indication of heart failure across 48 segments of the heart in 10 minutes. [4]
1/3
Enabling technologies
Footnotes
- www.escardio.org/The-ESC/Press-Office/Press-releases/Cancer-patients-are-at-higher-risk-of-dying-from-heart-disease-and-stroke
- Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., De Azambuja, E., De Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244.
- In an external study with external sonographers that compared the results of 18 exams with and without Auto Measure, Auto Measure reduced the time for standard measurements by up to 51%.
- Korosoglou G, et al. ESC Heart Failure. 2019 Aug;6(4):548-602.
- López-Fernández, T.MD Cardiac Imaging Laboratory, Cardio-oncology unit, Hospital La Paz Institute for Health Research, Madrid, Spain, “Using advanced ultrasound tools to assess CTRCD (cancer therapy-related cardiac dysfunction), 2020.
- Bringing 3D ultrasound into practice for cardiac quantification, Philips, 2018. https://www.philips.com.au/healthcare/white-paper/3d-ultrasound-for-cardiac-quantification. Fast-SENC is another name used for SENC.
- Using third party Myocardial Solutions (MyoStrain) software.
Disclaimer
*Copyright Myocardial Solutions, Inc. 2021. All rights reserved.
**HeartModel/Dynamic HeartModel, previously sold under the name HeartModel A.I., is an advanced automation solution, not currently certified as artificial intelligence.
***Philips Cardiovascular Workspace is the commercial name of the medical device Philips IntelliSpace Cardiovascular.